uniQure (NASDAQ:QURE) Announces Quarterly Earnings Results

uniQure (NASDAQ:QURE) posted its quarterly earnings results on Tuesday. The biotechnology company reported ($0.91) earnings per share for the quarter, beating the consensus estimate of ($1.12) by $0.21, Zacks reports. uniQure had a negative net margin of 1,027.52% and a negative return on equity of 158.09%. The business had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million.

uniQure Stock Up 3.8 %

QURE stock traded up $0.27 during midday trading on Thursday, hitting $7.43. The company’s stock had a trading volume of 1,363,612 shares, compared to its average volume of 1,414,395. The firm has a 50-day simple moving average of $5.70 and a 200-day simple moving average of $5.79. The firm has a market capitalization of $361.84 million, a P/E ratio of -1.27 and a beta of 0.90. The company has a quick ratio of 7.36, a current ratio of 7.36 and a debt-to-equity ratio of 1.06. uniQure has a 52-week low of $3.73 and a 52-week high of $11.35.

Analyst Upgrades and Downgrades

A number of research firms have commented on QURE. StockNews.com raised shares of uniQure to a “sell” rating in a research report on Thursday, October 17th. HC Wainwright restated a “buy” rating and issued a $25.00 price objective on shares of uniQure in a report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $28.00 target price on shares of uniQure in a report on Wednesday. Royal Bank of Canada decreased their price target on uniQure from $16.00 to $14.00 and set an “outperform” rating on the stock in a research note on Wednesday. Finally, The Goldman Sachs Group dropped their price objective on uniQure from $10.00 to $9.00 and set a “neutral” rating for the company in a research note on Wednesday. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $17.00.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.